deficit

CaCCinh-A01 是钙激活氯离子通道和TMEM16A 抑制剂，IC50值分别为 10 和 2.1 μM。

Oxidopamine hydrobromide (6-OHDA hydrobromide) 是一种神经递质多巴胺拮抗剂，可选择性地破坏多巴胺能神经元，是一种广泛使用的神经毒素。

Oxidopamine hydrochloride (6-Hydroxydopamine hydrochloride) 是一种神经递质多巴胺拮抗剂，可选择性地破坏多巴胺能神经元，是一种广泛使用的神经毒素。

Blonanserin (AD-5423) 是一种有效的5-HT2A 和多巴胺 D2 受体拮抗剂，Ki 为 0.812 和 0.142 nM，是一种非典型的抗精神病试剂。

Bavisant (JNJ-31001074) 是一种特异性和口服活性的人 H3 受体拮抗剂。 Bavisant 可用于作用机制的研究，包括觉醒和认知以及 ADHD 的治疗。

Guanfacine hydrochloride (Intuniv) 是一种 α2A 肾上腺素受体激动剂，Kd=31 nM，具有抗高血压作用。

SB 202190 (FHPI) 是一种 p38 MAPK 抑制剂，可以抑制 p38α 和 p38β2 (IC50=50 100 nM)，具有选择性和细胞渗透性。SB 202190 具有抗肿瘤活性，还可以诱导人胚胎干细胞向心肌细胞分化。

Brexpiprazole HCl (OPC 34712 dihydrochloride) 是一种新型抗精神病药物。

Perospirone (Lullan) 是具有口服活性的5-HT2A 受体和多巴胺 D2受体的拮抗剂，也是5-HT1A 受体的部分激动剂，Ki 分别为 0.6 、1.4和2.9 nM。它是一种非典型的抗精神病剂，可用于精神分裂症的研究。

TAK-041 (NBI-1065846) 是一种选择性 GPR139激动剂，EC50为 22 nM，有用于精神分裂症阴性症状的研究潜力。

MK-0249 是一种具有口服活性、选择性和高效性的 histamine H3 受体拮抗剂（IC50：1.7 nM），可用于研究注意力缺陷和多动障碍。

MK-0249 FA 是一种具有口服活性、选择性和高效性的组胺 H3 反向激动剂，可用于研究成人注意力缺陷、多动症神经分裂和认知障碍。

AR-08 是一种有效的 α2 肾上腺素能受体 (α2-adrenergic receptor) 激动剂，可用于研究多动症与注意力缺陷。

CX 717 是 AMPA 受体的正变构调节剂，具有抗抑郁样作用。CX 717 可用于成人注意力缺陷多动障碍（ADHD）的研究。

Cipralisant is a selective histamine H3 receptor antagonist in vivo, and an agonist in vitro (pKi: 9.9 for histamine H3 receptor; Ki: 0.47 nM for rat histamine H3 receptor). It has the potential for the treatment of attention-deficit hyperactivity disorde

Y13g 是白细胞介素 6 (IL-6) 和乙酰胆碱酯酶 (AChE)的有效抑制剂， 这两个靶点阿尔茨海默症 (AD) 进展的有关。Y13g 逆转 STZ 诱导的记忆缺陷，并表现出与正常动物相似的组织病理学。

SAR502250 is a potent, selective, ATP competitive, orally active and brain-penetrant inhibitor of GSK3, with an IC50 of 12 nM for human GSK-3β. SAR502250 displays antidepressant-like activity. SAR502250 can be used for the research of Alzheimer’s disease (AD)[1][2]. SAR502250 (0.01-1 μM; 36 h) attenuates the Aβ25-35-induced cell death in rat embryonic hippocampal neurons[2]. SAR502250 (1-100 mg kg; a single p.o,) attenuates tau hyperphosphorylation in the cortex and spinal cord of transgenic mice expressing P301L tau[2].SAR502250 (10-30 mg kg; p.o. once daily for 7 weeks) improves the cognitive deficit in transgenic APP(SW) Tau(VLW) mice after infusion of Aβ25-35[2].SAR502250 (10-30 mg kg; a single p.o.) significantly increases the percentage of lever-presses in the inter-response time (IRT) bin (49-96 s), with a significant augmentation of the percentage of reinforced responses[2].SAR502250 (30 mg kg; i.p. once daily for 28 d) ameliorates chronic stress-induced degradation of the physical state of the mice coat[2].SAR502250 (10-60 mg kg; a single p.o.) decreases hyperactivity produced by psychostimulantsin mice[2]. [1]. Fukunaga K, et, al. 2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3β inhibitors. Bioorg Med Chem Lett. 2013 Dec 15;23(24):6933-7.[2]. Griebel G, et, al. The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer’s disease in rodents. Sci Rep. 2019 Dec 2;9(1):18045.

MCI-225 is a norepinephrine reuptake 5-HT3 5-HT reuptake inhibitor. MCI-225 could be effective in the treatment of senile dementia of the Alzheimer type, which is accompanied with both deficit in the BF-cortex cholinergic neuron and cerebral glucose hypom

S-8510 is a GABA-A receptor inverse agonist. S-8510 selectively potentiated pentylenetetrazol-induced convulsion without affecting minimal electroconvulsive shock- or strychnine-induced convulsion in ddY mice. S-8510 ameliorated memory impairment induced

ABT-418, a nicotinic acetylcholine receptor (nAchR) agonist, is used potentially for the treatment of attention deficit disorder.

GSK3-IN-9 (0713) 是一种选择性抑制糖原合成酶激酶3 (GSK3) 的化合物。GSK3-IN-9 在脆性X综合征、注意缺陷多动障碍 (ADHD)、儿童癫痫、智力残疾、糖尿病、急性髓性白血病 (AML)、自闭症以及精神障碍等疾病的研究中具有潜在应用。

Sofinicline benzenesulfonate (ABT 894 benzenesulfonate) 为一种针对nAChR的α4β2亚型具有高选择性的烟碱型乙酰胆碱受体激动剂（IC50=0.1 nM）。该化合物展现了调节认知功能的能力，尤其是在改进注意力、记忆以及工作记忆方面。此外，Sofinicline benzenesulfonate 在对抗注意力缺陷及多动障碍（ADHD）的研究领域中具有重要应用价值。

Guanfacine-13C,15N3is intended for us as an internal standard for the quantification of guanfacine by GC- or LC-MS. Guanfacine is an α2-adrenergic receptor (α2-AR) agonist with Kivalues of 93, 1,380, and 3,890 nM for α2A-, α2B-, and α2C-ARs, respectively, in a radioligand binding assay.1It has EC50values of 52, 288, and 602 nM for α2A-, α2B-, and α2C-ARs, respectively, for stimulated [35S]GTPγS binding. It also binds to imidazoline receptor 1 (Ki= 19 nM in a radioligand binding assay).2Guanfacine (0.3-5 mg kg) binds to adrenergic receptors in the central nervous system and lowers blood pressure in hypertensive rats in a dose-dependent manner.3It also improves spatial working memory deficits induced by hypobaric hypoxia in rats.4Formulations containing guanfacine are used in the treatment of high blood pressure and attention deficit hyperactivity disorder (ADHD). 1.Jasper, J.R., Lesnick, J.D., Chang, L.K., et al.Ligand efficacy and potency at recombinant α2 adrenergic receptors: Agonist-mediated [35S]GTPγS bindingBiochem. Pharmacol.55(7)1035-1043(1998) 2.Nikolic, K., Filipic, S., and Agbaba, D.QSAR study of imidazoline antihypertensive drugsBioorg. Med. Chem.16(15)7134-7140(2008) 3.Scholtysik, G.Pharmacology of guanfacineBr. J. Clin. Pharmacol.10(Suppl 1)21S-24S(1980) 4.Kauser, H., Sahu, S., Kumar, S., et al.Guanfacine is an effective countermeasure for hypobaric hypoxia-induced cognitive declineNeuroscience254110-119(2013)

Samelisant dihydrochloride (SUVN-G3031) is a antagonist of histamine H3 receptor with potential for the treatment of cognitive impairment, dementia, attention deficit hyperactivity disorder, epilepsy, sleep disorders, obesity, schizophrenia, eating disorders, and pain.